26 / 43
26
During the maintenance phase, 54.2% (N=39) of patients received CTX administration every
two weeks and 45.8% (N=33) once a week (Estudio DIRECT)
•
Guigay J, et al. ESMO 2016 (Abstract 967P))
•
*Bi-weekly administration of cetuximab is off-label
Overall survival in maintenance phase
Progression-free survival in maintenance phase
12-month
OS rate %
(95% CI)
Weekly (n=21)
62.6 (43.6, 76.8)
Bi-weekly (n=31)
77.0 (59.1, 87.8)
12-month PFS, Logrank p=0.216
12-month OS, Logrank p=0.197
12-month
PFS rate %
(95% CI)
Weekly (n=6)
18.2 (7.4, 32.8)
Bi-weekly (n=12)
27.5 (14.3, 42.3)
Survival probability (%)
100
90
80
70
60
50
40
30
20
10
0
0
3
6
9
12
Time to event (months)
At risk
Time
Weekly
Bi-weekly
0
33
39
3
32
39
6
30
37
9
24
25
12
19
23
Survival probability (%)
100
90
80
70
60
50
40
30
20
10
0
0
3
6
9
12
Weekly
Bi-weekly
Weekly
Bi-weekly
Time to event (months)
0
33
39
3
31
38
6
20
28
9
11
14
12
6
9